Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clini… Read more
Anthera Pharmaceuticals Inc (ANTH) - Net Assets
Latest net assets as of March 2018: $5.46 Million USD
Based on the latest financial reports, Anthera Pharmaceuticals Inc (ANTH) has net assets worth $5.46 Million USD as of March 2018.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.81 Million) and total liabilities ($3.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.46 Million |
| % of Total Assets | 61.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -137.23% |
| 10-Year Change | N/A |
| Growth Volatility | 30.28 |
Anthera Pharmaceuticals Inc - Net Assets Trend (2007–2017)
This chart illustrates how Anthera Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anthera Pharmaceuticals Inc (2007–2017)
The table below shows the annual net assets of Anthera Pharmaceuticals Inc from 2007 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-12-31 | $-5.50 Million | -144.07% |
| 2016-12-31 | $12.47 Million | -68.56% |
| 2015-12-31 | $39.66 Million | +1853.96% |
| 2014-12-31 | $-2.26 Million | -115.32% |
| 2013-12-31 | $14.76 Million | +518.55% |
| 2012-12-31 | $-3.53 Million | -118.48% |
| 2011-12-31 | $19.08 Million | -66.67% |
| 2010-12-31 | $57.26 Million | +566.31% |
| 2009-12-31 | $-12.28 Million | -2567.79% |
| 2008-12-31 | $-460.26K | +92.15% |
| 2007-12-31 | $-5.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anthera Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39950075000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2017)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | % |
| Other Comprehensive Income | $-14.00K | % |
| Other Components | $428.93 Million | % |
| Total Equity | $-5.50 Million | 100.00% |
Anthera Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Anthera Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEW MAURITIUS HOTELS LTD
SEM:NMHL-O
|
$2.61K |
|
Relevant Gold Corp
PINK:RGCCF
|
$2.62K |
|
PHINMA Corp
PSE:PHN
|
$2.62K |
|
Crescent Steel & Allied Products Ltd
KAR:CSAP
|
$2.62K |
|
Royal Palms Beach Hotels PLC
CM:RPBHN0000
|
$2.61K |
|
Alexandria Spinning & Weaving (SPINALEX)
EGX:SPIN
|
$2.61K |
|
Blockchain Coinvestors Acquisition Corp. I Warrant
NASDAQ:BCSAW
|
$2.61K |
|
WASION GROUP HLDGS
BE:W1U
|
$2.60K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anthera Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2016 to 2017, total equity changed from 12,470,000 to -5,495,000, a change of -17,965,000 (-144.1%).
- Net loss of 16,935,000 reduced equity.
- Share repurchases of 270,000 reduced equity.
- Other comprehensive income decreased equity by 8,000.
- Other factors decreased equity by 752,000.
Equity Change Factors (2016 to 2017)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.93 Million | -308.19% |
| Share Repurchases | $270.00K | -4.91% |
| Other Comprehensive Income | $-8.00K | -0.15% |
| Other Changes | $-752.00K | -13.69% |
| Total Change | $- | -144.07% |
Book Value vs Market Value Analysis
This analysis compares Anthera Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $-248.00 | $0.00 | x |
| 2008-12-31 | $-19.46 | $0.00 | x |
| 2009-12-31 | $-519.21 | $0.00 | x |
| 2010-12-31 | $159.95 | $0.00 | x |
| 2011-12-31 | $32.64 | $0.00 | x |
| 2012-12-31 | $-3.90 | $0.00 | x |
| 2013-12-31 | $6.46 | $0.00 | x |
| 2014-12-31 | $-0.83 | $0.00 | x |
| 2015-12-31 | $8.90 | $0.00 | x |
| 2016-12-31 | $2.41 | $0.00 | x |
| 2017-12-31 | $-0.53 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anthera Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-119.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.11 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.05 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.98 Million |
| 2010 | -70.58% | 0.00% | 0.00x | 1.14x | $-46.14 Million |
| 2011 | -499.55% | 0.00% | 0.00x | 3.64x | $-97.24 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.05 Million |
| 2013 | -224.33% | 0.00% | 0.00x | 2.54x | $-34.58 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.08 Million |
| 2015 | -88.03% | -1096.14% | 0.07x | 1.21x | $-38.88 Million |
| 2016 | -429.86% | -36967.59% | 0.01x | 1.88x | $-54.85 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.39 Million |
Industry Comparison
This section compares Anthera Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anthera Pharmaceuticals Inc (ANTH) | $5.46 Million | 0.00% | 0.61x | $2.61K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |